CTOs on the Move

Bradford Health Services

www.bradfordhealth.com

 
Its never easy to admit that you or someone you care about is addicted to alcohol or drugs. But once you recognize the problem, the road to recovery appears at your feet. The first step down that road is to find professional help.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details
John Fisher
Chief Operating Officer Profile
Way Brunson
IT Director Profile

Similar Companies

Natrol

Natrol, Inc. (Natrol) manufactures and markets dietary supplements, herbal teas, and sports nutrition products under three primary brands: Natrol, Laci Le Beau, and Prolab. Through its Essentially Pure Ingredients (EPI) division, the Company sells

Bell Pharmaceuticals

Bell Pharmaceuticals is a Belle Plaine, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

UroGen

UroGen Pharma is a biopharmaceutical company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel™ drug delivery technology platform, our promising pipeline, and a collaborative drive for bold results. Our existing technology: the RTGel drug delivery platform has the potential to be applied to a variety of unmet medical needs. RTGel reverse-thermal hydrogel is liquid at lower temperatures and converts to gel form at body temperature, offering the opportunity to make local therapy a more effective treatment. Our promising pipeline: Ranging from pre-clinical to Phase III, we currently have multiple candidates in our pipeline, which are furthering the study of potential treatment advances in urology, uro-oncology, and immunology. Our collaborative drive: We are part of a broad ecosystem of partners who are seeking to improve patient care; these connections are vital to our commitment to offer new pathways and advance solutions. We currently have an exclusive worldwide license agreement with Allergan™ to evaluate the RTGel platform, an early-stage feasibility agreement with Janssen Pharmaceuticals™, and are continually evaluating new opportunities.

Immune Pharmaceuticals

Immune Pharmaceuticals is developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases.